Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Overview of attention for article published in Journal of Clinical Oncology, July 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 9 news outlets
policy: 1 policy source
twitter: 10 X users
patent: 4 patents

facebook: 3 Facebook pages
wikipedia: 2 Wikipedia pages
guideline: 4 clinical guideline sources

Readers on

mendeley: 422 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 11 X posts from 10 X users, with an upper bound of 169,320 followers.

It seems PAM50 is now PAM46. Why? "for proprietary reasons".... Now it is clearer. #BreastCancer http://t.co/kTcoIMgnp0

PAM50 found to stratify better than Oncotype for ER pos #BreastCancer http://t.co/Sl2Mpm0WlP

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 7 additional X posts.